13 results
8-K
EX-10.1
SDGR
Schrödinger, Inc.
12 Sep 24
Entry into a Material Definitive Agreement
4:32pm
. export controls (including, without limitation, the development, production or use of nuclear, chemical or biological weapons or missiles).
11.3. Force
424B4
SDGR
Schrödinger, Inc.
13 Aug 20
Prospectus supplement with pricing info
4:15pm
, a currently-approved therapy for lymphoma patients. Constant activation of nuclear factor-kappa B, or NF-kB, a key signaling molecule in B cells … of the HIF-2 alpha interaction with aryl hydrocarbon receptor nuclear translocator, or ARNT. We plan to continue advancing these molecules through
DRS
6x6bppgn qjbelix
31 Jul 20
Draft registration statement
12:00am
10-K
9hc9vdjuqd7hvysfttx
16 Mar 20
Annual report
4:37pm
424B4
gwbese
6 Feb 20
Prospectus supplement with pricing info
4:16pm
S-1
rew7fsu3 6ug
10 Jan 20
IPO registration
5:13pm
DRS/A
d69snz
13 Dec 19
Draft registration statement (amended)
12:00am
DRS
5t3sule 8b680
30 Oct 19
Draft registration statement
12:00am
- Prev
- 1
- Next